Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)

Thromb Haemost. 2011 May;105(5):763-5. doi: 10.1160/TH11-03-0159. Epub 2011 Mar 10.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / epidemiology*
  • Acute Coronary Syndrome / mortality*
  • Adenosine / analogs & derivatives*
  • Adenosine / therapeutic use
  • Clinical Trials as Topic
  • Clopidogrel
  • Epidemiologic Research Design
  • Europe
  • Humans
  • Patient Selection
  • Practice Guidelines as Topic
  • Statistics as Topic
  • Survival Analysis
  • Survival Rate
  • Ticagrelor
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Treatment Outcome
  • United States

Substances

  • Clopidogrel
  • Ticagrelor
  • Adenosine
  • Ticlopidine